Orthovita to Present at the Canaccord Adams 28th Annual Global Growth Conference

MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), a spine and orthopedic biosurgery company, announced today that it will present at the Canaccord Adams 28th Annual Global Growth Conference in Boston. Antony Koblish, chief executive officer of Orthovita, is scheduled to present on Wednesday, August 13^th, at 11:30 a.m. Eastern Time, at the Intercontinental Hotel Boston, 510 Atlantic Avenue, Boston, MA. A live webcast of the presentation will be available and can be accessed one hour after the presentation ends and for 90 days following the conference, by visiting the following website:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=***VITA& item_id=1887727. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

About the Company

Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS^® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material,and VITAGEL^® Surgical Hemostat, which is an adherent matrix and an impermeable barrier to blood flow. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS^® Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to treat vertebral compression fractures. We work jointly with Kensey Nash Corporation to develop and commercialize certain products based on our VITOSS platform, we market VITAGEL under a license agreement, we market VITASURE™ Absorbable Hemostat under a distribution rights agreement, and we continue to pursue similar relationships with other biomaterials companies.

Disclosure Notice

This press release may contain forward-looking statements regarding Orthovita’s current expectations of future events that involve risks and uncertainties, including, without limitation, the development, regulatory approval, demand and market acceptance of our products; our ability to obtain FDA clearance for CORTOSS in the United States; and other aspects of our business. Such statements are based on management’s current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements. Other factors that may cause such a difference are listed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K under the caption "Risks Factors”. Further information about these and other relevant risks and uncertainties may be found in Orthovita’s filings with the SEC, all of which are available from the SEC as well as other sources. Orthovita undertakes no obligation to publicly update any forward-looking statements.

Orthovita, Inc.
Albert J. Pavucek, Jr.
Chief Financial Officer
610-640-1775 or 800-676-8482